Amplification and Overexpression of Elongin C Gene Discovered in Prostate Cancer by cDNA Microarrays

Functional significance of several oncogenes is mediated by overexpression. To identify overexpressed genes in prostate cancer, we analyzed expression of 1081 transcripts in three prostate cancer cell lines (PC-3, DU145, and LNCaP) using cDNA microarray hybridization. The cDNA microarray analyses were validated by quantitative real-time RT-PCR. On average, 64% of the genes were expressed at detectable levels in the cell lines. Next, the expression profiles were combined with the data on DNA sequence copy number alterations in the cell lines obtained by comparative genomic hybridization. The genes for Elongin C and urokinase type plasminogen-activator, both located in the regions of amplification in the PC-3 cell line (8q21 and 10q22, respectively), were found to be overexpressed in the PC-3. Amplification and overexpression of urokinase type plasminogen-activator in prostate cancer has previously been reported. Here, fluorescence in situ hybridization on tissue microarray showed high-level amplification of the Elongin C gene in 8 (23%) of 35 hormone-refractory carcinomas but in none of the untreated prostate carcinomas (n = 35). Finally, it was shown that the Elongin C gene was overexpressed and amplified also in breast cancer cell line SK-Br-3. The results indicate that Elongin C is a putative target gene for 8q amplification.

[1]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[2]  M. Groudine,et al.  Tumor suppression and transcription elongation: the dire consequences of changing partners , 1995, Science.

[3]  T. Visakorpi,et al.  Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. , 1998, Cancer genetics and cytogenetics.

[4]  Michael L. Bittner,et al.  Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Visakorpi,et al.  Mapping the amplification of EIF3S3 in breast and prostate cancer , 2000, Genes, chromosomes & cancer.

[6]  A. Mazar,et al.  Expression of Urokinase and Its Receptor in Invasive and Non-Invasive Prostate Cancer Cell Lines , 1992, Thrombosis and Haemostasis.

[7]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[8]  C. Larsson,et al.  5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines , 2001, Genes, chromosomes & cancer.

[9]  S. Reed,et al.  Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. , 2000, Cancer research.

[10]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[11]  M. Schwab,et al.  Oncogene amplification in tumor cells. , 1986, Advances in cancer research.

[12]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[13]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[14]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[15]  O. Kallioniemi,et al.  Genome screening by comparative genomic hybridization. , 1997, Trends in genetics : TIG.

[16]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[17]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[18]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[19]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[20]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[21]  M. Maqueo Topete,et al.  [Renal carcinoma]. , 1959, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[22]  R. Conaway,et al.  A human cDNA encoding the small subunit of RNA polymerase II transcription factor SIII. , 1994, Gene.

[23]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[24]  M. Wigler,et al.  Cloning the differences between two complex genomes , 1993, Science.

[25]  R. Conaway,et al.  RNA polymerase II transcription factor SIII. I. Identification, purification, and properties. , 1993, The Journal of biological chemistry.

[26]  J W Gray,et al.  Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[28]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[29]  H. Tanke,et al.  Identification of Genetic Markers for Prostatic Cancer Progression , 2000, Laboratory Investigation.

[30]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[31]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[32]  T Visakorpi,et al.  Molecular genetics of prostate cancer. , 2001, Annals of medicine.

[33]  Mark M. Davis,et al.  Isolation of cDNA clones encoding T cell-specific membrane-associated proteins , 1984, Nature.

[34]  T. Visakorpi,et al.  Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. , 2001, The American journal of pathology.

[35]  K. Porkka,et al.  Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. , 1999, The American journal of pathology.

[36]  Francis S. Collins,et al.  Positional cloning moves from perditional to traditional , 1995, Nature Genetics.

[37]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  William Arbuthnot Sir Lane,et al.  Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II , 1995, Science.

[39]  B. Eussen,et al.  Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. , 2000, Journal of the National Cancer Institute.

[40]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[41]  T. Visakorpi,et al.  Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.

[42]  M Hubank,et al.  Identifying differences in mRNA expression by representational difference analysis of cDNA. , 1994, Nucleic acids research.

[43]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[44]  T. Tammela,et al.  Amplification of urokinase gene in prostate cancer. , 2001, Cancer research.

[45]  A. Pardee,et al.  Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. , 1992, Science.